Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) (SATISFACTION)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00727259|
Recruitment Status : Completed
First Posted : August 1, 2008
Results First Posted : August 6, 2009
Last Update Posted : April 29, 2015
|Condition or disease||Intervention/treatment|
|Hepatitis C, Chronic||Biological: Peginterferon alfa-2b (SCH 54031) Drug: Ribavirin (SCH 18908)|
|Study Type :||Observational|
|Actual Enrollment :||1995 participants|
|Official Title:||Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C|
|Study Start Date :||October 2004|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||April 2008|
Patients with chronic hepatitis C
Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
Biological: Peginterferon alfa-2b (SCH 54031)
Peginterferon alfa-2b will be administered according to the products' labeling.
Other Names:Drug: Ribavirin (SCH 18908)
Ribavirin will be administered according to the products' labeling.
Other Name: Rebetol
- Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months [ Time Frame: The patient was instructed to answer and return by mail the first self-questionnaire after 1 month of treatment and the second one after 3 months of treatment. ]Patient satisfaction for each item on the questionnaires was rated on a scale from 0 (not satisfied) to 7 (very satisfied).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00727259
|Study Director:||Clinical Director||Merck Sharp & Dohme Corp.|